184 related articles for article (PubMed ID: 19675719)
41. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
42. Performance of immunoassays for ca 19-9, ca 15-3 and ca 125 tumour markers evaluated from an international quality assessment survey.
Pilo A; Zucchelli GC; Cohen R; Chiesa MR; Bizollon CA
Eur J Clin Chem Clin Biochem; 1996 Feb; 34(2):145-50. PubMed ID: 8833648
[TBL] [Abstract][Full Text] [Related]
43. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
44. External quality assurance of the carcinoembryonic antigen (CEA) assay: main findings in six years' experience.
Zucchelli GC; Ferdeghini M; Pilo A; Clerico A; Masini S; Prontera C
Int J Biol Markers; 1992; 7(3):154-9. PubMed ID: 1431338
[TBL] [Abstract][Full Text] [Related]
45. Urine tests for Down's syndrome screening.
Alldred SK; Guo B; Takwoingi Y; Pennant M; Wisniewski S; Deeks JJ; Neilson JP; Alfirevic Z
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011984. PubMed ID: 26662198
[TBL] [Abstract][Full Text] [Related]
46. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals.
Erden G; Barazi AO; Tezcan G; Yildirimkaya MM
Scand J Clin Lab Invest; 2008; 68(3):212-8. PubMed ID: 17926198
[TBL] [Abstract][Full Text] [Related]
47. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
48. Clinical application of tumour markers: a review.
Amayo AA; Kuria JG
East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
[TBL] [Abstract][Full Text] [Related]
49. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
Tappero G; Piantino P; Cerchier A; Pecchio F
Minerva Med; 1985 Apr; 76(16):765-70. PubMed ID: 2582313
[TBL] [Abstract][Full Text] [Related]
50. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
51. [The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].
Iarŭmov N; Ignatov A; Viiachki I
Khirurgiia (Sofiia); 1998; 51(3):42-8. PubMed ID: 9974027
[TBL] [Abstract][Full Text] [Related]
52. Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500.
Zur B; Holdenrieder S; Walgenbach-Brünagel G; Albers E; Stoffel-Wagner B
Clin Lab; 2012; 58(1-2):97-105. PubMed ID: 22372351
[TBL] [Abstract][Full Text] [Related]
53. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract][Full Text] [Related]
54. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review.
Laraib U; Sargazi S; Rahdar A; Khatami M; Pandey S
Int J Biol Macromol; 2022 Jan; 195():356-383. PubMed ID: 34920057
[TBL] [Abstract][Full Text] [Related]
55. Elecsys CEA, PSA and AFP. Clinical results of a multicentre evaluation.
Uhl W; Chan DW; Jones K; Kelley C; Assmann G; von Eckardstein A; Sägers A; Yvert JP; Schneider AM; Torralba A; Fuentes-Arderiu X; Gonzalez de la Presa B; Vives M; Greiling H; Eberle A; Niederau CM; Cremer P; Reiter W; Vogeser M; Neumeier D; Luppa P; Huber U
Wien Klin Wochenschr; 1998; 110 Suppl 3():51-61. PubMed ID: 9677672
[TBL] [Abstract][Full Text] [Related]
56. Italian external quality assessment scheme in immunoassay.
Pizzocolo G; Albertini A; Malvano R; Signorini C; Zucchelli G
Ann Ist Super Sanita; 1995; 31(1):123-9. PubMed ID: 8546360
[TBL] [Abstract][Full Text] [Related]
57. Strategies for five tumour markers in the screening and diagnosis of female breast cancer.
Luo J; Xiao J; Yang Y; Chen G; Hu D; Zeng J
Front Oncol; 2022; 12():1055855. PubMed ID: 36755860
[TBL] [Abstract][Full Text] [Related]
58. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer.
Louhimo J; Carpelan-Holmström M; Alfthan H; Stenman UH; Järvinen HJ; Haglund C
Int J Cancer; 2002 Oct; 101(6):545-8. PubMed ID: 12237895
[TBL] [Abstract][Full Text] [Related]
59. Estimation of inter-laboratory reference change values from external quality assessment data.
Paal M; Habler K; Vogeser M
Biochem Med (Zagreb); 2021 Oct; 31(3):030902. PubMed ID: 34393596
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
